Zidovudine (3' -azido-2' ,3' -dideoxythymidinc) is a drug with provcd antihuman immunodeficicncy virus (HIV) reverse traßscriptase activity. It has bcen clearly demonstrated that thc bcnefits of zidovudinc outwcigb the risks of its usc. H Different adversc effeets have bcen reponed for zidovudine, including anacmia, neutropenia. nausea, vomiting, myalgias, abnormalities of livcr funetion, bluish nail pigmentation, headachcs, myositis, and trichiasis." Colom vision deficits have bcen reponed for patients with AIDS or HIV disease," and it has been shown that this defect is most prominent for tritan vision.' The patbogencsis of eolour vision defieits in patients with HIV disease remains unclear. We wish to repon the occurrenee of a temporary decrease in tritan colour contrast sensitivity in two patients with HIV disease starting or restarting treaunent with zidovudine.
Casereports OASE 1 A 31-year-old patient was referred to the university eye hospital for routine examination after diagnosis of HIV infection and Iymphadenopathy syndrome. Tbe patient had attended the medical outpatient clink because of a 1 month history of fever aeeompanicd by swcUing of lymph nodes. He tested HIV positive for the first time during this diagnostic examination whieh was 2 wecks before lhc first ophthalmie examination. Visual acuity was 20120 in both eyes with correction. Biomicroscopic examination revealed normal findings except for a discrete sludging of the blood column in the conjunctival vessels. On indirect ophthalmoscopy five cotton wool spots were seen in the right eye, and one in the left eye. Colour contrast scnsitivity was tested using a high sensitivity computer graphlcs system devcloped by Ardcn et al. ' o Tbe thresholds for the three colour 3XCS were within normal limits: tritan right eye (RE) 4·7, and left eye (LE) 4·2; deutan RE 3·3, and LE 3·2; protan RE 3·0, and LE 3·1. Tbe age corrected normal mucs 3ft (mean (2 SE»): tritan 3·9 (2·2); deutan 4·3 (2·2); and protan 4·0 (1·9). Tbe absolute CD4+ Iymphocytc count was 219 x 10'11, and treatment with zidovudine (500 mg per day) was staned. Thls was the only drug administered to the patient. Seven days after initiation of treatment with zidovudine the patient attended hospital with a 3 day experienee of sligbtly blurred vision in both eycs. Ophthalmie examination, and deutan and protan colour vision were unchanged, but tritan vision was impaired: tritan RE 7·4,and LE 7·S. Zidovudine treatment was continued. One weck later the subjective symptoms disappearcd. Tritan thresholds were REj·4, and LE 4·6. On subS;CQuent foUow ups tritan vision improved to baseline levels, and was in a range betwecn 3·7 and 4· 3 in both eyes. OASE 2 Tbe second patient was a 26-year-old woman with a 9 month history of AIDS after one episode of Pnewnocystis carinii pneumonia. She was referred to the university eye hospital for ophthalmie examination because of diplopia. Treatment with zidovudine bad been discontinued 2 months earlier because of neutmpenia, but the patient was still on Pneumocystis cannii prophylaxis with trimethoprim and sulphamethoxazole. Tbe absolute CD4+ Iymphocyte count was 70x 10"11. Visua1 acuity was 20120 in both eyes with correction. Ophthalmie examination revealed a sixth nerve palsy of the right eye. Otherwise ophthalmie examination was nonnal and colouf contrast sensitivity thresholds were within nonnallimits: tritan RE 3·g, and LE 3·9; deutan RE 3·6, and LE 3·6; protan RE 3·7. and LE 3·7.
Cranial magnetic resonance imaging showed a lesion in the area of the right pons and a second lesion in the left anterior part of the corpus eallosum, both with surrounding oedema. Clear ring-like enhancement was seen after application of Gd-DTPA. The location of the lesion in the pons was in accordance with compressive damage to the intracerebral path of the sixth nervc. Thc diagnosis of cerebral toxoplasmosis was assumed, and treatment with pyrimethamine (50 mg per day), c1indamycin (2400 mg per day), and folinic acid (15 mg per day) was started. Ten days later diplopia disappeared. Treatment with zidovudine (500 mg per day) was re-establisbed 2 months later. Tritan COIOUf contrast sensitivity increased to RE 6·4, and LE 6·5 measured 3 days after the reJ.D.luauon of treatment with zidovudine, but otherwise ophthalmie findings were normal, especially the values for deutan and protan vision. Two weeks later tritan eolour contrast sensitivity was RE 3'5, and LE 3·8 and other findings were unehanged.
Comment
Alterations of eolour vision bave been reported for numerous drugs."" Aequired alterations of tritan vision are usually related to retinal damage." Tberefore, the dyschromatopsia in the (Wo reported cases is expected to be related to retinal damage.
Recently, retinal damage bas been reported for ehildren treated with 2' ,3' -dideoxyinosine." The authors used electropbysiological methods to measure retinal funetion, but no testS for colour vision were perfonned. They suggest that 2' ,3'-dideoxyinosine, whieh is also a dideoxynucleoside like zidovudine, causes a diffuse dysfunction of the retinal pigment epithelium.
The pathogenesis of eolour vision deficits in patients with symptomatic HIV infection or AIDS remains unclear. It was proposed that the HIV-related retinal mieroangiopathic syndrome plays an importaDt role in the pathogenesis of those colour vision deficits. Our observations suggest that a temporary shift in tritan colour vision is an adverse effect at the beginning of treatment with zidovudine. Tbis shift in tritan vision might be due to a temporary interference of zidovudine with the production of visual pigment, or a temporary alteration of the pigment epithelium. Nevertheless, other factors may underly the changes. It cannot be ruled out that long tenn application of zidovudine might contribute to the development of colour vision deficits described for patients with HIV disease. Health care professionals involved in the treatment of patients with HlV disease sbould be aware of any abnormal deug or disease related effects.
